United States
United States rescheduling of cannabis awaits further administrative decisions
FDA-approved products face separate measures while broader reclassification remains under review.
The United States is pursuing separate pathways for cannabis rescheduling. Following April 2026 measures for FDA-approved marijuana pharmaceuticals, a DEA administrative hearing commenced in June 2026 to evaluate moving all cannabis from Schedule I to Schedule III. Legal challenges in the federal appeals court continue alongside this administrative process.
Key developments in US rescheduling
FDA-approved product measures
In April 2026, the United States announced specific Schedule III measures concerning pharmaceutical products containing marijuana that have received FDA approval.
Broader reclassification hearing
An administrative hearing by the DEA commenced on 29 June 2026 to address the transition of all marijuana from Schedule I to Schedule III.
Parallel legal challenges
Federal appeals court litigation is currently proceeding alongside the DEA administrative hearings regarding the proposed rescheduling of cannabis.
Our view
We publish this partly to correct a claim that circulates widely. The United States has not moved all cannabis to Schedule III. The April 2026 measures concern FDA-approved marijuana pharmaceuticals and specified state-licensed marijuana; the broader reclassification is a separate administrative process, subject to a hearing that began in June 2026 and to parallel litigation. No conclusion has been reached. For a company whose work depends on clinical research, the significance of reclassification lies in what it would do to research approvals, not in the symbolism. We will not report a decision until one is made.
Background
The current situation stems from the dual tracks of cannabis regulation in the United States. While specific pharmaceutical formulations have already been addressed, the complete transition of cannabis to Schedule III requires a distinct administrative and legal process that is still ongoing.
Sources
Get the latest medical cannabis news by email
We send AMI updates and research summaries once a week.
